- Home
- BCAB vs MLSS Comparison
BCAB vs MLSS Comparison
Compare BCAB & MLSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | MLSS |
|---|---|---|
| Founded | 2007 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8M | 20.8M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BCAB | MLSS |
|---|---|---|
| Price | $0.19 | $0.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.00 | $1.00 |
| AVG Volume (30 Days) | ★ 2.6M | 155.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $300,000.00 | ★ $8,629,928.00 |
| Revenue This Year | N/A | $8.95 |
| Revenue Next Year | N/A | $7.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.13 | $0.22 |
| 52 Week High | $1.43 | $1.12 |
Technical Indicators
Market Signals| Indicator | BCAB | MLSS |
|---|---|---|
| Relative Strength Index (RSI) | 36.94 | 47.28 |
| Support Level | $0.13 | $0.23 |
| Resistance Level | $0.57 | $0.31 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 58.96 | 48.36 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About MLSS Milestone Scientific Inc.
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.